GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hunan Er-Kang Pharmaceutical Co Ltd (SZSE:300267) » Definitions » Other Net Income (Loss)

Hunan Er-Kang Pharmaceutical Co (SZSE:300267) Other Net Income (Loss) : ¥0 Mil (TTM As of Mar. 2025)


View and export this data going back to 2011. Start your Free Trial

What is Hunan Er-Kang Pharmaceutical Co Other Net Income (Loss)?

Hunan Er-Kang Pharmaceutical Co's Other Net Income (Loss) for the three months ended in Mar. 2025 was ¥0 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Mar. 2025 was ¥0 Mil.

Hunan Er-Kang Pharmaceutical Co's quarterly Other Net Income (Loss) increased from Sep. 2024 (¥0 Mil) to Dec. 2024 (¥0 Mil) but then declined from Dec. 2024 (¥0 Mil) to Mar. 2025 (¥0 Mil).

Hunan Er-Kang Pharmaceutical Co's annual Other Net Income (Loss) increased from Dec. 2022 (¥0 Mil) to Dec. 2023 (¥0 Mil) and increased from Dec. 2023 (¥0 Mil) to Dec. 2024 (¥0 Mil).

Hunan Er-Kang Pharmaceutical Co Other Net Income (Loss) Historical Data

The historical data trend for Hunan Er-Kang Pharmaceutical Co's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hunan Er-Kang Pharmaceutical Co Other Net Income (Loss) Chart

Hunan Er-Kang Pharmaceutical Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Other Net Income (Loss)
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Hunan Er-Kang Pharmaceutical Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Other Net Income (Loss) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Hunan Er-Kang Pharmaceutical Co Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hunan Er-Kang Pharmaceutical Co Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of Hunan Er-Kang Pharmaceutical Co's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Hunan Er-Kang Pharmaceutical Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hunan Er-Kang Pharmaceutical Co Ltd (SZSE:300267) » Definitions » Other Net Income (Loss)
Comparable Companies
SZSE:300725 SZSE:002390 SHSE:603367 SZSE:002365 SZSE:000813 SZSE:300039 SZSE:002038 SHSE:688553 SZSE:000566 SZSE:000915 ZTS XTER:MRK LSE:HLN NSE:SUNPHARMA TSE:4502 XSWX:GALD XSWX:SDZ NSE:DIVISLAB HKSE:03692 XTAE:TEVA
Traded in Other Exchanges
N/A
Address
Kangping Road 167, National Economic and Technological Development Zone, Liuyang Changsha, Hunan, CHN, 410331
Website
http://www.hnerkang.com
Hunan Er-Kang Pharmaceutical Co Ltd develops, produces and sells pharmaceutical products in China. The company's main products include pharmaceutical excipients and antibiotics. It offers pharmaceutical excipients, APIs and finished drug products. The pharmaceutical excipients include products such as glycerol, ethanol pharmaceutically, acceptable propylene glycol, sodium hydroxide, and pharmaceutically acceptable sugar. The company's finished drugs primarily include sulbenicillin sodium for injection and compound liquorice tablets. Its APIs include glycerin, dilute hydrochloric acid, dihydroxypropyl theophylline, sulbenicillin sodium, calamine powder, sulfadiazine, sulphaguanidine, TMP, and resorcinol. Geographically, all the activities are carried out through China.
Executives
Shuai Fang Wen Director
Wang Jun Wen Independent director
Zuo Tian Fang Independent director
Qi Yang Supervisors
Li Yi Guo Supervisors
Chen Wen Xian Supervisors
Wang Xiang Feng Directors, executives
Liu Ai Jun Directors, executives
Luo Lang Directors, executives
Fan Yi Securities Affairs Representative
Yang Hai Ming Directors, executives
Shuai You Wen Director
Shuai Rui Wen Director
Gao Zhen Ya Executives
Cao Zai Yun Director

Hunan Er-Kang Pharmaceutical Co Headlines

No Headlines